Details of the Drug

General Information of Drug (ID: DMP45ME)

Drug Name
Lisocabtagene maraleucel
Synonyms JCAR017
Indication
Disease Entry ICD 11 Status REF
Large B-cell lymphoma 2A81 Approved [1]
Central nervous system lymphoma 2B33.5 Phase 2 [2]
Follicular lymphoma 2A80 Phase 2 [2]
Non-hodgkin lymphoma 2B33.5 Phase 2 [3]
Richter syndrome 2A81.Y Phase 2 [2]
Precursor B-lymphoblastic neoplasm 2A70 Phase 1/2 [4]
⏷ Show the Full List of Indication(s)
Drug Type
CAR T Cell Therapy
Cross-matching ID
DrugBank ID
DB16582
TTD ID
D0M4WU
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Large B-cell lymphoma
ICD Disease Classification 2A81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
2 ClinicalTrials.gov (NCT03484702) Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma
3 ClinicalTrials.gov (NCT03310619) A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
4 ClinicalTrials.gov (NCT03743246) A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)